AstraZeneca heads to regulators after Airsupra asthma trial stops early thanks to 'overwhelming efficacy'

After winning a first-in-class nod for its two-drug inhaler Airsupra last January, AstraZeneca is adding to the thesis that the drug can cut the risk of asthma exacerbations regardless of disease severity.